Rebounding stocks: Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) up 8.67% Accenture PLC (NYSE:ACN) AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)

Posted by Ryan Mandell April 19, 2013 0 Comment 1956 views


Northern, WI 04/19/2013 (GDPInsider) –  Accenture PLC (NYSE:ACN) opened at $75.39 and is currently trading down at 1.10%. The modest slip is nothing too alarming given the trading day’s range of $74.21 – $75.39. The stock is in relatively healthy territory given the fact that the 52-week trading range is actually $54.94 and $78.46. At current trading it means that the stock is only down 3.91% on its 52-week high. With a RSI of 43.80 and a positive EPS of $4.29, investors can take the plunge without need for too much worry. The current trading value sees Accenture’s stock just dipping 1.24% below the 50-day moving average. The stock has also been receiving steady “buy” ratings from several key analysts and news that the company has launched a “Center of Excellence” aimed at helping companies reduce the cost of implementing software systems; the stock looks a solid buy going forward. Rounding out the soundness of the stock is market cap of $48.59 billion.

Is ACN a solid investment at these levels? Find out here.

Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) is up a solid 8.67% or $0.2290 and is currently trading at $2.8860 a share. Acura opened at $2.74 and the stock has a current trading range of $2.65 and $2.95.  Given the day’s opening value, Acura looks a solid offer for anyone looking to capitalize on small swings. The stock’s 52-week trading range of $1.06 and $4.50 means that current trading is down 39% on the 52-week high but a great improvement on its lowest recorded mark. Investors no doubt see this as a positive move and the trading value and volume duly reflects this. Today’s volume is a healthy 870,405 and the stock is 19.13% above the 50-day moving average of $2.30. Acura may be small cap at $134 million but the stock has been a beneficiary of a recent FDA decision. The stock chart saw a 50% breakout on the news and although there’s currently a negative EPS of $0.20, analysts expect things to liven up in the coming months.

How Should Investors Trade ACUR Now? Find out here.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) opened at $7.37 and is presently trading down 47.66% on the 52-week high of $14.08. The trading range for the stock is presently $7.31 and $7.55, a range which sees more than 1,154,360 shares changing hands. Things look marginally steady over time for the stock and the current trading value of $7.37 means AVEO is hovering slightly above its 50-day moving average of $7.25. AVEO Pharmaceuticals’ chart for the last 3 months has seen peaks and troughs but things seem to steadying for the month of April. The RSI for the stock is 5.34 and the stock currently has a negative EPS of $2.64. Analysts seem divided on the stock but a few of issued a “sell” rating. News that the stock is now been covered by JMP Securities a few weeks ago means that more people will be watching. Investors should therefore have enough data and sentiment to decide on whether to jump in. Losses for FY2012 were $21,480 but this figure showed a decline in losses over the previous year of $30,122.

How Should Investors Trade AVEO Now? Find out here.

 


About Ryan Mandell

Ryan Mandell is our senior staff writer covering the White House for Political Report, Ryan also coordinates with the main newsroom news items and contributing write-ups on cultural, social and political activities. Ryan holds an undergraduate degree in journalism, a Doctorate in international relations and a Master Degree in mass communications with an emphasis in print journalism. Ryan also covered the International Society of Social Defense congress in Spain in 2007 and taken part in the Global Forum on economic policies

View all post by Ryan Mandell Visit author's website

Write Your Comment